MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

52.17

+0.29 (0.56%)

Dec 20, 2024, 4:00 PM EST - Market closed

MLTX Employees

MoonLake Immunotherapeutics had 50 employees as of December 31, 2023. The number of employees increased by 30 or 150.00% compared to the previous year.

Employees

50

Change (1Y)

30

Growth (1Y)

150.00%

Revenue / Employee

n/a

Profits / Employee

-$1,615,362

Market Cap

3.29B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	50	30	150.00%
Dec 31, 2022	20	-	-

Related Stocks

Company Name	Employees
Envista Holdings	12,800
Oscar Health	2,400
NovoCure	1,453
Inari Medical	1,300
Veracyte	815
Denali Therapeutics	445
CRISPR Therapeutics AG	407
Rhythm Pharmaceuticals	226

Employee Rankings

MLTX News

3 months ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
5 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
7 months ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire
8 months ago - MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion - Seeking Alpha
8 months ago - MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
9 months ago - MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions - GlobeNewsWire
9 months ago - MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions - Business Wire
10 months ago - MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day - GlobeNewsWire